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Abstract
Background: Genetic variation of matrix metalloproteinase 9 (MMP-9) gene polymorphism has been suggested to
modulate coronary heart diseases (CHD), yet the underlying mechanisms are not well understood.
Methods: We investigated the association of MMP9 rs3918242 single nucleotide polymorphism with inflammation
and lipid-lowering efficacy after simvastatin treatment in Chinese patients with CHD. Fasting serum lipid profile and
plasma inflammatory mediators were determined at baseline in 264 patients with CHD and 186 healthy control
subjects, and after HMG-CoA reductase inhibitor simvastatin treatment (20 mg/day) for 12 weeks in CHD subjects.
Results: We found that plasma MMP-9, TNF-α and IL-10 levels were significantly elevated in patients with CHD
compared to control subjects before treatment. The plasma MMP9 in CHD patients carrying rs3918242 CC, CT
and TT genotypes were comparable. Interestingly, CHD patients carrying TT genotype had significantly higher
level of triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) than those carrying CC genotype (P <0.05).
Simvastatin treatment significantly reduced LDL-C, TG and plasma inflammatory mediator levels in CHD patients. The
reduction of LDL-C upon simvastatin therapy was significantly greater in patients carrying TT genotype than those
carrying CC genotype (P <0.05).
Conclusions: MMP9 rs3918242 TT genotype is associated with elevated serum TG and LDL-C, and enhanced
LDL-C-lowering response upon simvastatin treatment in Chinese patients with CHD.
Clinical trial registration: This study was retrospectively registered at Chinese Clinical Trial Registry (Registration number:
ChiCTR-ROC-17010971) on March 23rd 2017.
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Background
The matrix metalloproteinases (MMPs) are a family of
zinc-dependent endopeptidases collectively capable of
degrading essentially all components of extracellular
matrix [1]. One of the MMP family member, MMP9, has
been shown to involve in the pathogenesis of cardio-
vascular diseases [2, 3]. Furthermore, MMP9 SNP
rs3918242 and circulating MMP9 level are associated
with coronary heart disease (CHD) progression and MI,
arterial stiffness and cardiovascular disease mortality in
patients with CHD [4–7], while the mechanisms are not
completely understood.
CHD is characterized by elevated circulating pro-in-
flammatory mediators including TNF-a and IL-6, and re-
duced anti-inflammatory mediators, such as IL-10 [8]. The
imbalance of pro-inflammatory and anti-inflammatory
mediators contributed to CHD progression [9]. Several
lines of evidence suggest a potential link of plasma MMP9
activity to plasma TNF-a level, and a negative association
with plasma IL-10 level in chronic inflammatory condi-
tions [10]. However, whether MMP9 rs3918242 poly-
morphism is associated with altered plasma MMP9 level* Correspondence: Xueqili2016@outlook.com
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and plasma inflammatory mediators in the Chinese pa-
tients with CHD has not been characterized [11].
The clinical beneficial effects of statin therapy in redu-
cing the risk of coronary events and mortality in patients
with coronary artery disease are believed to be the result
of its cholesterol-lowering and anti-inflammatory actions
[12, 13]. Studies have shown that statin therapy reduces
circulating MMP9 level in CHD patients and decreases
MMP9 secretion in experimental conditions [14, 15]. It is
still unclear if the decreased MMP9 level or activity upon
statin therapy might merely correlate with or modulate its
lipid-lowering efficacy in patients with CHD.
In this study, we examined the association of MMP9
rs3918242 polymorphism on MMP9 level, lipid profiles
and inflammatory mediators in the blood in response to
simvastatin therapy in Chinese patients with CHD.
Methods
Research participants
The research protocol was approved by the Ethics Com-
mittee of Harbin Medical University. We recruited 264
coronary heart diseases patients (112 females, 152 males;
55–78 years old), who underwent coronary angiography
in the fourth clinical hospital of Harbin medical univer-
sity. Written informed consent was obtained from all the
participants with a full explanation of the study. Coron-
ary arteriograms were interpreted by two or more inde-
pendent, experienced cardiologists in a blinded manner.
CHD was defined as over 50% stenosis in at least one
major vessel. The inclusion criteria were: (1) diagnosed
of CHD (2) strictly abstained from smoking, alcohol and
caffeine during treatment. The exclusion criteria were
(1) subjects who had taken or were currently taking
HMG-CoA reductase inhibitors; (2) individuals with
liver or kidney failure or subject to liver or kidney trans-
plantation, diabetes mellitus, dropsical nephritis and di-
agnosed myocardial infarction; (3) subjects who had
taken any other lipid-lowering medication within
2 months before the study were also excluded. The
control population consisted of 186 healthy subjects
(90 females, 96 males; 52–79 years old) who had rou-
tine health check at medical examination center.
Blood collection and biochemical analysis
All subjects were asked to take low-fat diet and adminis-
tered simvastatin 20 mg per oral ever day at bedtime.
Fasting serum lipids were determined before and after
12 weeks of statin treatment. Total cholesterol (TC), tri-
glyceride (TG), high-density lipoprotein cholesterol
(HDL-C), low density lipoprotein cholesterol (LDL-C)
and very low density lipoprotein cholesterol (VLDL-C)
in plasma were measured by enzymatic methods using
an auto-analyzer. Plasma glucose levels were measured
using an automated glucose oxidase method described
before. Serum MMP9 levels were measured by enzyme-
linked immunosorbent assay (ELISA) using the monoclo-
nal antibody against MMP9 [16]. The plasma TNF-α level
was quantified using a sandwich ELISA kit (rat TNF-α/
TNFSF1A, Duoset, R&D Systems, Abington, UK) and IL-
10 level was assessed using the ChemiArray Rat Cytokine
Antibody Array I kit (Chemicon-Millipore).
Genotyping of human MMP-9 gene 1562C >
T polymorphism
Genomic DNA was extracted from peripheral blood
mononuclear cells (PBMCs). The MMP9 gene rs3918242
polymorphism was determined by polymerase chain
reaction-restriction fragment length polymorphism (PCR-
RFLP) based protocol [13]. Briefly, a 435 bp region in the
promoter of MMP-9 gene, −1809 to −1374 upstream of
MMP-9 transcription start site (TSS), was amplified. For-
ward primer 5′-GCCTGGCACATAGTAGGCCC-3′, re-
verse primer 5′-CTTCCTAGCCAGCCGGCATC-3′. The
amplification reaction mix included 20 ng genomic DNA,
dNTP (0.8uM), forward and reverse primer (0.5uM each),
Prozyme DNA polymerase (0.5 unit) in the PCR buffer.
PCR reaction was performed according to manufacturer’s
manual. Aliquots of the PCR product were then fragmen-
ted using SphI restriction enzyme, and the the digestion
products were analyzed by 2% agarose gel electrophoresis.
Statistical analysis
All statistical analyses were performed with SPSS soft-
ware (version 13.0; SPSS, Chicago, IL, USA). Allele fre-
quencies were estimated by gene counting. ANOVA was
applied to compare average values of biochemical pa-
rameters between genotypes; Chi-square test was used
to compare genotype and gene frequencies between the
groups. Comparison between control and CAD subjects
were performed using student’s T test. Comparison of
parameters before and after statin treatment were con-
ducted using paired student’s T test. All data were pre-
sented as the mean ± SD. A two-tailed P-value < 0.05 was
considered as statistically significant for all analyses.
Results
Genotype and allele frequencies of MMP9-1562C/T in
CHD patients and controls
We recruited 264 CHD patients who underwent coron-
ary angiography in the fourth clinical hospital of Harbin
Medical University during 2013–2014 (112 females, 152
males; age range 55–78 years). 186 control subjects were
age and sex-matched healthy subjects who had a routine
health check at the medical examination center of Har-
bin Medical University (90 females, 96 males; age range
52–79 years). Genotyping for MMP9 rs3918242 poly-
morphism were performed in all the CHD subjects using
the genomic DNA extracted from peripheral blood
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leukocytes (Fig. 1). The genotype distributions in pa-
tients with CHD and controls were present in Hardy-
Weinberg equilibrium. As shown in Table 1, the geno-
type and allele frequencies of MMP9 rs3918242 poly-
morphism were similar between the control subjects and
patients with CHD (P > 0.05).
Baseline clinical characteristics of patients with CHD
and control subjects
Table 2 summarizes the clinical characteristics of the
CHD patients and control subjects. All patients had at
least one risk factor for coronary artery disease, includ-
ing smoking, alcohol abuse and lack of exercise. Coron-
ary heart disease was strongly associated with smoking
(CHD patients compared with controls: P <0.05). At
baseline, patients with CHD had significantly higher
levels of serum TG, TC, LDL-C, VLDL-C, MMP-9,
TNF-α and IL-10 and lower level of HDL-C than control
subjects (P <0.05).
Effects of simvastatin on plasma lipids and MMP-9,TNF-α
and IL-10
After 12-weeks simvastatin treatment in combination
with the low-fat diet, serum TG, TC, LDL-C and VLDL-
C levels were significantly decreased and the HDL-C
level was increased in patients with CHD. Furthermore,
plasma MMP9, TNF-α and IL-10 were also markedly re-
duced in CHD patients (Table 3).
Influence of the MMP9 rs3918242 polymorphism on
plasma levels of lipid and inflammatory mediators
Given that MMP9 rs3918242 polymorphism has been
suggested to regulate MMP expression [17, 18], we first
determined the effect of the rs3918242 polymorphism on
plasma MMP9 level. The average level of MMP9 in sub-
jects with TT genotype was similar to subjects carrying
CT and CC genotypes in this cohort (Table 4 and Fig. 2A).
Serum TG and LDL-C levels of patients carrying TT geno-
type were significantly increased compared to patients car-
rying CC genotype (P <0.05), while HDL-C, VLDL-C, TC,
TNF-α and IL-10 levels were comparable in three groups
before statin treatment (Table 4 and Fig. 2B). Statin treat-
ment significantly elevated plasma HDL-C, and reduced
the levels of LDL-C, TG, TC and VLDL-C in three groups
of CHD patients. Notably, the reduction of LDL-C in
patients carrying TT genotype was more robust than the
LDL-C reduction in patients carrying CC genotype after
statin treatment (34.53% vs. 24.23%, P <0.05). Interest-
ingly, the reduction of TG, TC, VLDL-C, MMP-9, TNF-α
and IL-10 were similar in three groups of patients
(Table 4). These findings revealed a novel link of MMP9
rs3918242 TT genotype to the increased serum LDL-C
and TG at baseline, and more robust LDL-C-lowering
response to statin treatment compared to CHD patients
carrying CC genotype.
Discussion
In this study, we showed that CAD patient carrying
MMP9 rs3918242 TT genotype had significantly in-
creased plasma TG and LDL-C levels than patients
Fig. 1 Genotyping of the matrix metalloproteinase 9 rs3918242 by
polymerase chain reaction-restriction fragment length polymorphism
(PCR-RFLP). Lane 1&5:heterozygote CT;lane 2, 3&6:homozygote
CC;lane 4:homozygote TT
Table 1 Genotype and allele frequencies of MMP9 rs3918242 in
CHD and control subjects
Group n Genotype Allele
CC (%) CT (%) TT (%) C (%) T (%)
Controls 186 151 (81.2) 31 (16.7) 4 (2.1) 333 (89.5) 39 (10.5)
CHD 264 188 (71.3) 69 (26.0) 7 (2.7) 445 (84.3) 83 (15.7)
CHD coronary heart disease, MMP-9 matrix metalloproteinase-9






Sex (M:F) 96: 90 152: 112
Age (years) 58 ± 10.72 59 ± 11.67
Waist (cm) 86.25 ± 6.03 88.11 ± 5.97
Height (cm) 171.28 ± 5.39 169.15 ± 6.62
Weight (kg) 70.04 ± 7.91 71.24 ± 7.35
Body mass index (kg/m2) 23.98 ± 2.93 24.73 ± 2.86
Systolic blood pressure (mmHg) 123 ± 19 125 ± 21
Diastolic blood pressure (mmHg) 60 ± 17 65 ± 18
Heart rate 64 ± 15 67 ± 16
Fasting glucose (mmol/l) 4.35 ± 1.02 4.62 ± 1.31
Smoking 45 (24.19%) 109 (41.23%)*
Alcohol abuse 26 (14.05%) 43 (16.27%)
Data are means ± SD. *P <0.01 compared with control group. CHD coronary
heart disease
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carrying CC genotype, and their LDL-C lowering response
to simvastatin treatment were more robust than patients
with CC genotype. These findings revealed a novel link of
the MMP9 SNP polymorphism to LDL-C lowering re-
sponse to simvastatin treatment in CHD patients.
Studies have consistently supported the correlation of
MMP-9 rs3918242 polymorphism correlated with in-
creased susceptibility to a variety of diseases [19–21],
including coronary artery diseases [22]. The previous
study also revealed that MMP-9 rs3918242 polymorph-
ism was associated with the susceptibility to acute cor-
onary syndrome (ACS) in the Uygur population of
China [23]. In the present study, we examined the effects
of the MMP9 rs3918242 polymorphism on plasma
MMP-9 level before and after simvastatin treatment in
Chinese CHD patients. We found that plasma MMP-9
levels were elevated in patients with CHD compared to
control subjects, and simvastatin treatment reduced
plasma MMP-9 in CHD patients. However, MMP9 levels
in patients with different MMP9 rs3918242 polymorph-
ism were comparable before and after simvastatin treat-
ment. Early studies revealed that the MMP9 rs3918242
CC genotype was responsible for lower activity of MMP-
9 and genotypes with the T allele (CT, TT) were respon-
sible for higher activity [18, 24]. The T-alleles’ effect on
circulating MMP-9 levels exclusively in obese and lack of
such influence in lean people has further been reported
[25, 26]. Because the recruited CHD patients in the
current cohort were not obese (average BMI = 24.73), our
report further confirmed that the T-allele’s effect on circu-
lating MMP9 level were lacking in non-obese people.
Studies in humans and animal models have provided
evidences for a significant involvement of in atheroscler-
otic plaque progression, through degrading extracellular
matrix, destabilizing advanced atherosclerotic plaques
and facilitating vascular smooth muscle cell migration
and proliferation [3, 27, 28]. Emerging evidences suggest
Table 3 Plasma lipid profile and inflammatory mediators before




CHD group (n = 264)
Before treatment After treatment
TG (mmol/l) 1.15 ± 0.35 1.58 ± 0.58* 1.14 ± 0.71§
TC (mmol/l) 4.11 ± 0.37 5.14 ± 0.49* 4.35 ± 0.53§
HDL-C (mmol/L) 1.37 ± 0.31 1.10 ± 0.25* 1.29 ± 0.27§
LDL-C (mmol/L) 2.00 ± 0.51 3.1 ± 0.27* 2.32 ± 0.30§
VLDL-C (mmol/L) 0.75 ± 0.21 1.03 ± 0.24* 0.78 ± 0.16§
MMP-9 (ng/ml) 40.78 ± 9.72 78.17 ± 21.43* 60.32 ± 20.30§
TNF-α (pg/ml) 81.23 ± 39.07 136.95 ± 52.41* 102.37 ± 47.19§
IL-10 (pg/ml) 32.18 ± 12.15 98.65 ± 34.79* 50.31 ± 24.28§
Values are expressed as mean ± SD. Comparison between controls and CHD
subjects were by unpaired student T-test; comparison between before and
after treatment of statin were by paired student T-test. *P <0.0001 compared
with control group; §P <0.0001 compared with before treatment. CHD coronary
heart disease, MMP9 matrix metalloproteinase 9, IL-10 interleukin-10, TNF-α
TNF-alpha, TC total cholesterol, TG triglyceride, HDL-C high density lipoprotein
cholesterol, LDL-C low density lipoprotein cholesterol, VLDL-C very low density
lipoprotein cholesterol
Table 4 Effect of simvastatin in CHD patients with MMP-9 rs3918242 polymorphism
week CC (n = 188) CT (n = 69) TT (n = 7)
Mean ± SD % Change Mean ± SD % Change Mean ± SD % Change
TG (mmol/L) 0 1.52 ± 0.19 28.13 ± 3. 1.73 ± 0.25 28.19 ± 3.0 1.87 ± 0.27* 28.12 ± 3.22
12 1.11 ± 0.21 29 1.21 ± 0.18 7 1.39 ± 0.23
TC (mmol/L) 0 5.15 ± 0.61 18.24 ± 2. 5.11 ± 0.59 18.59 ± 3.0 5.12 ± 0.51 18.71 ± 3.26
12 4.34 ± 0.47 67 4.36 ± 0.49 6 4.37 ± 0.56
HDL-C (mmol/L) 0 1.10 ± 0.19 15.23 ± 2. 1.09 ± 0.18 14.87 ± 2.6 1.13 ± 0.21 15.61 ± 2.42
12 1.29 ± 0.23 54 1.29 ± 0.22 1 1.29 ± 0.22
LDL-C (mmol/L) 0 3.09 ± 0.26 24.23 ± 5. 3.13 ± 0.28 27.50 ± 4.4 3.38 ± 0.37* 34.53 ± 4.0
12 2.35 ± 0.32 78 2.27 ± 0.24 4 2.10 ± 0.26* 0*
VLDL-C (mmol/L) 0 1.04 ± 0.16 34.16 ± 4. 1.01 ± 0.19 34.89 ± 4.5 1.08 ± 0.23 35.14 ± 4.6
12 0.79 ± 0.09 31 0.75 ± 0.11 7 0.81 ± 0.13 9
MMP-9 (ng/ml) 0 76.28 ± 21.26 24.38 ± 6.59 82.28 ± 21.26 23.10 ± 9.27 88.28 ± 22.47 22.37 ± 7.82
12 58.75 ± 20.21 63.75 ± 20.21 68.75 ± 20.21
TNF-α (pg/ml) 0 134.73 ± 51.38 26.48 ± 4.11 137.08 ± 55.63 25.07 ± 5.12 135.98 ± 60.12 24.46 ± 2.99
12 100.26 ± 49.34 106.65 ± 50.04 99.65 ± 43.87
IL-10 (pg/ml) 0 100.13 ± 36.17 47.33 ± 9.28 95.08 ± 34.79 52.04 ± 11.62 103.35 ± 40.14 48.27 ± 10.56
12 51.28 ± 26.21 47.29 ± 29.06 53.91 ± 22.38
Values are expressed as mean ± SD. *P <0.0001 compared with the CC genotype by one-way ANOVA followed with Bonferroni post-hoc test for pair-wise comparison.
§P <0.0001 compared with before treatment by paired student’s t-Test. HD coronary heart disease, MMP-9 matrix metalloproteinase-9, TC total cholesterol, TG triglyceride,
HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, VLDL-C very low density lipoprotein cholesterol
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that MMP-9 is also involved in lipoprotein modification
during progression of atherosclerotic lesions [29]. Higher
levels of MMP-9 have been consistently observed to cor-
relate with increasing total cholesterol or LDL-C levels
in humans and animal models [30, 31], suggesting a po-
tential link of MMP-9 rs3918242 polymorphism to
serum LDL-C. In this study, we showed that CHD pa-
tients with MMP-9 rs3918242 genotype had elevated
serum TG and LDL-C levels before simvastatin treat-
ment. More important, we showed that patients with TT
genotype had significantly more robust LDL-C lowering
effect in response to simvastatin treatment than those
with CC genotype. Although the association of LDL-C
level with MMP9 polymorphism has been reported in
other studies [32, 33], this study is the first to demon-
strate that MMP9 polymorphism is associated with
LDL-C lowering efficacy after simvastatin treatment, and
thus provides new evidences on the link of genetic varia-
tions to the efficacy of lipid lowering medications.
This study has several limitations. (1) All the CHD pa-
tients were given simvastatin in combination with low-fat
diet intervention. Therefore, the LDL-C lowering effect
could possibly be biased by the diet intervention. Future
studies without diet intervention would be helpful to ad-
dress this problem. (2) The current CHD cohort contains
41.23% current smokers. It was reported that MMP9 level
in the blood was significantly higher in current smokers
compared to never and former smokers [34]. Hence, it
would be important to analyze the serum MMP9 level
and LDL-C lipid lowering effect with further stratification
for smoking. (3) Patients in this cohort were uniformly
treated with the medium dose of simvastatin (20 mg/day)
for 12 weeks, and their serums LDL-C was significantly
reduced to the level comparable to the control subjects. In
this context, we found that patients carrying MMP9
rs3918242 TT genotype had more robust LDL-C-lowering
response to statin treatment compared to patients carry-
ing CC genotype. It would be interesting to examine
whether the association of genetic variation of MMP9
rs3918242 with simvastatin’s LDL-C lowering response
was dose-dependent. We expected improved LDL-C-
lowering response of MMP9 rs3918242 T-allele to simva-
statin even at lower dose.
Conclusions
In conclusion, MMP9 rs3918242 T-allele is associated
with elevated plasma TG, increased LDL-C and improved
LDL-C-lowering response to simvastatin treatment in
Chinese patients with CHD. Further studies with larger
sample sizes are required to confirm these findings and to
explore the underlying mechanisms.
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